Potential overestimation of plasma non-esterified fatty acid levels (NEFA). The effect of in-vitro lipoprotein lipase inhibition with tetrahydrolipstatin on NEFA in heparinized patients undergoing percutaneous coronary interventions.

Potential overestimation of plasma non-esterified fatty acid levels (NEFA). The effect of in-vitro lipoprotein lipase inhibition with tetrahydrolipstatin on NEFA in heparinized patients undergoing percutaneous coronary interventions. - NEFA concentrations during primary PCI for acute myocardial infarction.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31946

Enrollment

Registered

2008-05-27

Start date

2008-03-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Non-diabetic and diabetic patients with acute myocardial infarction undergoing primary percutaneous coronary angioplasty

Exclusion criteria

Exclusion criteria: Participation in another clinical research study within 30 days of enrollment. Hemoglobine level

Design outcomes

Primary

Measure	Time frame
The degree of difference between NEFA levels analyzed in the absence and presence of THL in the test tube during blood sampling	—

Secondary

Measure	Time frame
LPL APTT	—

Countries

Netherlands

Outcome results